Depending on the method used, rare sequence variants adjacent to the single nucleotide polymorphism (SNP) of interest may cause unusual or erroneous genotyping results. Because such rare variants are known for many genes commonly tested in diagnostic laboratories, we organized a proficiency study to assess their influence on the accuracy of reported laboratory results.
RESULTS:
One hundred eighty-nine laboratories participated in the study. When samples gave a usual result with the method applied, the error rate was 5.1%. Detailed analysis showed that more than 70% of the failures were reported from only 9 laboratories. Allele-specific amplification-based PCR had a much higher error rate than other methods (18.3% vs 2.9%). The variants 20209CϾT and [20175TϾG; 20179_20180delAC] resulted in unusual genotyping results in 67 and 85 laboratories, respectively. Eighty-three (54.6%) of these unusual results were not recognized, 32 (21.1%) were attributed to technical issues, and only 37 (24.3%) were recognized as another sequence variant.
CONCLUSIONS:
Our findings revealed that some of the participating laboratories were not able to recognize and correctly interpret unusual genotyping results caused by rare SNPs. Our study indicates that the majority of the failures could be avoided by improved training and careful selection and validation of the methods applied.
© 2009 American Association for Clinical Chemistry
Common functional single nucleotide polymorphisms (SNPs) 6 are associated with predisposition to highincidence multifactorial disorders or altered drug metabolism and play an essential role in the diagnostic process, risk stratification, and treatment selection. These genetic alterations are usually tested using DNAbased genotyping techniques, which are designed for accurate and rapid detection of the SNP of interest and not intended for mutation screening. Although these assays are highly specific, rare variants adjacent to the nucleotide of interest may cause unusual or erroneous genotyping results (1) (2) (3) (4) (5) . Such rare variants are known, for example, in genes coding factor V (6) (7) (8) , hemochromatosis (9, 10 ) , factor II (prothrombin) (5, (11) (12) (13) (14) , and cholesterol ester transfer protein (CETP) (1 ) . However, their influence on the accuracy of reported laboratory results has not yet been investigated.
The Institute for Reference Materials and Measurements (IRMM) and the Department of Biochemistry of the University of Szeged agreed on a proficiency testing (PT) study in cooperation with 3 European external quality assessment (EQA) organizations to assess how clinical laboratories interpret unusual genotyping results and how many of these laboratories recognize interfering mutations and report them correctly. Additional aims of the study were to identify weaknesses of genetic testing services, to develop QC materials for rare variants, and to gather more information about the requirements for DNA-based candidate reference materials (RMs).
Recently, in a collaborative effort, the Scientific Committee of Molecular Biology Techniques in Clinical Chemistry of the IFCC and the IRMM have developed a set of 3 plasmid-type certified reference materials (CRMs) for the analysis of the 20210GϾA (G20210A) mutation in F2, the coagulation factor II (prothrombin) gene (15) (16) (17) (18) (19) . These plasmids contain a wild-type or G20210A mutant prothrombin gene fragment that spans all primer annealing sites published to date.
The G20210A mutation in the 3Ј untranslated region of the prothrombin gene is associated with higher mean plasma prothrombin concentrations and increased risk for thrombotic diseases (20 ) . The clinical significance of the presence of this SNP, indications for testing, and therapeutic consequences of the results have been reviewed (21 ) . Because no specific functional (e.g., clotting) tests exist, the analysis of this SNP in the course of initial evaluation of suspected inherited thrombophilia is one of the most frequently performed genetic tests in clinical laboratories; all the EQA organizations contacted offer surveys for this test in their molecular diagnostic schemes.
Other variants of the prothrombin gene, such as 20209CϾT (22, 23 ) 20218AϾG (14 ) , and 20221CϾT (12 ), are relatively rare (detected in 1 in 1660 samples). The C20209T mutation accounts for nearly 85% of these variants. These and similar mutations can result in unusual genotyping results, and the correct reporting and interpretation of these cases could be an important indicator of the competence of testing laboratories.
Materials and Methods

PRODUCTION OF THE EXTERNAL QC SAMPLES
Development and processing of the wild-type and G20210A mutant plasmid CRMs has been reported (15 ) . These plasmids include a well-characterized fragment of the human prothrombin gene (GenBank M17262; nucleotide position 26 302-26 910) comprising the SNP of interest and spanning all published primer annealing sites.
We introduced the C20209T mutation into the wild-type sequence using the QuikChange II SiteDirected Mutagenesis Kit (Stratagene) according to the manufacturer's recommendations, with 2 complementary oligonucleotides as mutagenesis primers. The sense oligo was 5Ј-CCCAATAAAAGTGACTCTCAG TGAGCCTCAATGCTCCCAGTGC-3CЈ (mutagenic nucleotide is underlined) (Proligo Biochemie GmbH). Plasmids were transfected and cultured in XL1-Blue supercompetent cells provided in the kit.
We screened plasmid preparations purified from the cultured and harvested bacteria using the Qiagen QIAfilter Plasmid Maxi Kit (Qiagen Benelux B.V.) for the presence of mutations resulting in unusual melting curves on the LightCycler ® with the Prothrombin (G20210A) Mutation Detection Kit (Roche Diagnostics) according to the kit insert. Two plasmids containing newly introduced mutations were sequenced using suitable primers (Profw, 5Ј-GCACAGACGGCTGT TCTCTT-3Ј, and Prorev, 5Ј-CCCGAGTGCTCGGAC TACCA-3Ј; synthesized by VBC Genomics, Vienna, Austria; HPLC-purified) and CEQ Dye Terminator Cycle Sequencing Kit with the Beckman CEQ8000 Sequencer (Analis) according to the manufacturer's instructions. Purity of plasmid preparations was confirmed by the OD 260/280 ratio, and DNA concentration was determined using an Eppendorf Biophotometer (VWR International). We mixed plasmids containing the newly introduced mutations with equal amounts of the G20210A mutant or wild-type plasmids. These plasmid preparations were diluted in Tris-EDTA buffer (10 mmol/L, 1 mmol/L, pH 8.0) to a final concentration of approximately pg/L DNA. Before aliquoting these diluted stocks, we tested them again on the LightCycler system as described above.
DESIGN OF THE RING TRIAL
Four external quality control materials were aliquoted (30 L/vial) into sterile, self-standing, high-recovery 1.5-mL polypropylene screw-cap vials and distributed to each of the 283 laboratories participating in 3 European EQA schemes (DGKL Referenzinstitut für Bioanalytik, Bonn, Germany; Instand e.V., Düsseldorf, Germany; and QualiCont Kht., Szeged, Hungary). (The actual number of laboratories invited for this exercise was likely lower due to overlapping coverage of the same laboratories by multiple schemes.)
Two of the 4 materials contained mutations giving unusual genotyping results when using some methods: sample A, 20210A/[20175TϾG; 20179_20180delAC], heterozygous for the G20210A mutation; sample B, G20210/C20209T, homozygous wild-type for the G20210A mutation; sample C, 20210A/20210A, homozygous for the G20210A mutation; and sample D, G20210/G20210, homozygous wild-type for the G20210A mutation.
Participants were informed that the external QC samples contained plasmid-type materials but were given no information on the expected results. Using a standard form, testing laboratories were asked to give information on the type of the center activity, spectrum of the tests offered, accreditation status of the laboratory, number of genetic tests performed yearly (factor II G20210A and in general); dates of arrival and testing; storage conditions; and incidental comments/observations on the samples. The laboratories were asked to describe in detail the methods applied (including the sample processing protocol and genotype and origin of the controls used) and submit their genotyping results including the raw data (e.g., copy of the gels, melting curves). No standardized terms for the reporting were defined. Further comments on the results were welcomed.
Statistical analysis of the study results was performed by 2 -test, and the significance limit was set to P Ͻ 0.05.
Results
PRODUCTION OF THE NEW QC MATERIALS
Screening of plasmid preparations detected 2 new variants displaying unusual melting peaks at approximately 54°C and 58°C. Sequencing of these plasmids identified the newly introduced mutations identified as C20209T and [20175TϾG; 20179_20180delAC] mutations, respectively. Of note, the second mutation was not introduced by site-directed mutagenesis, but occurred accidentally. This quite complex variation leads to a decrease of the melting temperature of the anchor probe, resulting in a relatively sharp melting peak. 
PROFICIENCY TESTING STUDY
After removal of duplications resulting from the overlap of laboratories participating in more than 1 EQA scheme, 189 laboratories from 21 countries participated in the survey. Some features of the participants are shown in Table 1 . These laboratories applied a large variety of genotyping techniques, representing 50 different analytical procedures. All of the assays could amplify the target sequence from the plasmids, proving that the samples were suitable for the interlaboratory comparison exercise.
Genotyping results are summarized in Table 2 and can be split into usual and unusual results after analysis. Usual results have typical genotyping outcomes (e.g., in terms of sequence) or test system responses (e.g., melting curve or bands on the electropherogram), which correspond to one of the expected genotypes, namely homozygous wild-type (G20210/G20210), heterozygous (G20210/20210A), or homozygous G20210A mutant (20210A/20210A) with the surrounding sequence being conserved and being present in the vast majority of individuals. Results are called unusual when the presence of a sequence variant or the test system response did not correspond to expectations for the majority of individuals, such as abnormal melting curves, unexpected nucleotide sequences, or a band of unanticipated size in the electropherogram.
More detailed analysis of the results showed that the performance of the individual laboratories did not depend on the type of the laboratory, the spectrum of tests offered, or the accreditation status of the laboratory (data not shown). Table 3 displays the use of different genotype controls in the participant laboratories. Results where the test system response (e.g., melting curve or electropherogram) were as expected and corresponding to homozygous wild-type (G20210/G20210), heterozygous (G20210/20210A), or homozygous G20210A mutant (20210A/20210A) genotype. These results were not influenced by the sequence variants in samples A and B. c In 67 and 85 laboratories for samples A and B, respectively, the sequence variants affected the methods, and unusual genotyping results (e.g. abnormal melting curves or electropherogram, unexpected nucleotide changes in sequencing data) were obtained that should have been detected and reported accordingly. Some of these unusual results were detected and reported either as "technical issues" or "recognized variants"; however, many participants did not describe these atypical observations and reported the results as one of the expected genotypes without additional remarks. d NA, not applicable. e Reported as one of the expected genotypes, but the sequence variant resulted in an atypical genotyping pattern using the technique applied. f Genotypes not reported but observations described such as unusual results of presumed technical origin.
USUAL RESULTS
Genotyping assays for detection of the G20210A mutation in the prothrombin gene usually result in the genotypes homozygous wild-type (G20210/G20210), heterozygous (G20210/20210A), or homozygous G20210A mutant (20210A/20210A). All the methods provided such results on samples C and D, and the majority of the techniques also on samples A and B. Among these results, the error rate was 5.1%, which corresponds to previous observations in the literature (26) (27) (28) (29) . Interestingly, the error rates were higher on samples A and C containing the G20210A mutation (6.4% and 6.3%, respectively) than on samples B and D without the G20210A mutation (2.9% and 4.3%, respectively); however, this difference was not statistically significant.
Currently, commercial kits as well as several laboratory developed tests (LDTs) are used for identification of the prothrombin G20210A mutation. Table 4 presents the error rates on usual results using the different techniques. The most frequently applied methods were LightCycler [fluorescence resonance energy transfer (FRET)], reverse hybridization, and PCR-RFLP. Reverse hybridization assays were carried out using commercial kits. Sixty of the 78 LightCycler users applied the Roche Factor II (Prothrombin) G20210A mutation detection kit. Among PCR-RFLP methods, most of the laboratories applied the original method published by Poort et al. (20 ) or its slightly modified versions, whereas only 4 laboratories used an improved method (30 ) , which contains an additional restriction site for digestion control. Although more laboratories used commercial kits for PCR-RFLP and allele-specific PCR than LDTs, approximately 63% of the prothrombin G20210A tests were performed in laboratories employing LDTs. It should be emphasized that the difference in error rates for commercial and laboratorydeveloped tests was not found to be statistically significant.
Allele-specific amplification PCR showed a much higher error rate than other methods (18.3% vs 2.9%), and 6 of 15 laboratories (40%) using this technique reported false results. No statistically significant differences in performance were seen between commercial kits and LDTs. Although these findings cannot be explained only by shortcomings of the technique, the method appears to be less reliable.
Altogether, 30 incorrect genotypes were reported by 19 participants for results with a usual genotyping pattern (Table 4 ). Further analysis of these results showed that 21 (70%) of these failures were obtained from only 9 laboratories.
Two of these laboratories reported the results using inappropriate nomenclature indicating only the presence or absence of the G20210A mutation and did not distinguish the heterozygous from the homozygous G20210A mutation. Such results were not considered to be adequately and correctly reported (31 ) because the different risk levels associated with the heterozygous or homozygous genotypes may influence clinical decisions.
Careful comparison of available raw data and genotypes reported revealed that 2 participants mixed up findings postanalytically. In 2 other cases, the genotypes were assigned incorrectly, but the raw data showed technically correct results. One laboratory employing an allele-specific PCR kit submitted results despite having incorrect findings on the control samples. One participant using an inappropriately designed LightCycler assay mistyped 3 samples.
UNUSUAL RESULTS
Detailed analysis of the results obtained for sample A revealed that the [20175TϾG; 20179_20180 del AC] mutation interfered with the assay applied in 67 laboratories, leading to unusual genotyping results. In addition, most results from the 10 laboratories using the TaqMan allelic discrimination (AD) assays indicated an impaired amplification of the wild-type sequence due to the [20175TϾG; 20179_20180delAC] mutation.
Sixty laboratories employed the LightCycler instrument with the LightCycler Prothrombin G20210A Mutation Detection Kit (Roche), and 1 more participant used a laboratory-developed method similar to that applied in this kit. Using these methods, the [20175TϾG; 20179_20180delAC] mutation led to a decrease of the melting temperature of the anchor probe, which resulted in a melting peak at approximately 1.7°C lower than expected for the wild-type allele (Fig. 1) . Although this peak was inside the range of 59 (2.5)°C indicated by the manufacturer, the difference between the wild-type and the mutant melting peaks did not fall into the range specified in the kit instructions [10 (1.5)°C]. Probably because of the small deviation from the expected values, only 23% of the laboratories reported unusual melting peaks on this sample. Approximately half of these laboratories noted that such unusual melting peaks could indicate a variant in the probe region.
Three laboratories used sequencing as their routine procedure. In addition, one of the LightCycler users, observing the unusual melting curves, sequenced the region to identify the variant. All 4 laboratories could identify the mutation, although in 1 case it was not correctly described.
One laboratory applied a denaturing HPLC (dHPLC) assay. This participant detected the presence of the variant, but mistyped the 20210A mutant allele as wild-type in sample A.
Two laboratories using PCR-RFLP methods with high-resolution electrophoresis (PAGE or Agilent Labon-chip) found a double band instead of the expected single band on the wild-type allele. This second band probably corresponded to the undigested heteroduplex of the 2 alleles, which had a moiety with lower electrophoretic mobility due to the loop arising from the mismatches. Both laboratories noted this unusual finding.
Ten of the participating laboratories used different TaqMan AD assays. Seven of these laboratories reported a homozygous mutant (20210A) genotype on sample A, 1 participant genotyped the sample as heterozygous (G20210/20210A), and 2 laboratories, upon finding unusual AD plots, genotyped the sample by PCR-RFLP. The few available raw data (for 2 of the 10 laboratories) revealed that the sequence alteration in the sample A led to a shift in the AD plot depending on the primer sequences. In cases where AD plots were affected, amplification of the wild-type sequence was probably inefficient because of the impaired primer binding due to the [20175TϾG; 20179_20180delAC] mutation. The lack of raw data did not allow further evaluation of the results from AD assays on sample A.
The C20209T mutation in sample B gave unusual genotyping results in 85 laboratories. Seventy-eight of these laboratories applied the LightCycler technique with 6 different methods. Owing to the C20209T mutation, the melting peak was located at approximately 54°C using the Roche Factor II (Prothrombin) G20210A mutation detection kit. In 3 published LightCycler-based assays, the melting peak is at approximately 60°C for the wild-type allele, whereas for the G20210A mutation, it is located close to 53°C. Using these methods, the C20209T variant appeared as a peak at approximately 50.5°C; however, this peak was smaller than the usual ones, which might render the evaluation of these results slightly more difficult.
Seven participants tested the samples by sequencing as standard procedure. Four of these assays were minisequencing techniques (e.g., pyrosequencing) determining only a few bases adjacent to the mutation of interest. One of the pyrosequencing methods was not able to detect the C20209T mutation. Only 1 of 6 other laboratories performing sequencing reported the C20209T mutation, although it could clearly be identified on the basis of the raw data provided. Two participants sequenced this sample because of the unusual melting curves they obtained using the LightCycler. The returned sequences identified the C20209T mutation.
One laboratory used PCR-dHPLC technique without and with addition of wild-type sequences. This participant reported sample B as heterozygous for the G20210A mutation (wild-type/20210A) because this sample gave a chromatographic pattern that could not be distinguished from the heterozygous G20210A samples.
Although a majority of laboratories did not report genotypes when they experienced unusual results on samples A and B, other participants recognized the presence of the sequence variants or attributed the unusual behavior of the assay to technical issues, including poor quality or low concentration of the DNA. The other techniques used for genotyping in 93 of 179 laboratories (52.0%) were not influenced by the additional mutations in samples A and B.
Discussion
Both method validation and internal/external quality control require samples of known genotypes. However, access to samples carrying rare genotypes (such as the homozygous 20210A mutation in the prothrombin gene) or harboring rare SNPs (such as the 20209T allele) is limited (32 ) . The restricted availability may contribute to the relatively high number of failures in the identification of G20210A mutant genotypes (both heterozygous and homozygous forms). Therefore, the availability of CRMs or QC samples is of prime importance. Three plasmid-based CRMs whose suitability has been carefully assessed are now available from IRMM (http://www.irmm.jrc.be) for testing of the G20210A mutation (16) (17) (18) . The plasmids are designed in a way that they can be used for all methods published up to 2006. Based on these plasmid-type RMs, the desired mutations could be introduced using the site-directed mutagenesis technique, allowing the design of test samples with rare genotypes/mutations.
Quality issues in human genetic testing are particularly important because these tests are carried out in principle only once in a lifetime and false results can lead to inadequate treatment or preventive measures. EQA is the key mechanism to assess the performance of diagnostic medical laboratories and the efficiency of their testing methods. Ring trials also serve as educational tools and training for the participants to sustain improvements in the quality of services. Despite these efforts, relatively high error rates for clinical genetic testing of thrombophilic mutations have been reported, which persist at approximately 5% without any notable improvement in recent years (26) (27) (28) (29) .
Overall, the results of this interlaboratory comparison showed expected error rates on the wild-type and G20210A mutation samples without additional mutations. This error rate on the detection of SNPs may result in thousands of misclassifications yearly in the participant laboratories, which emphasizes the need for more detailed scrutiny to identify sources of errors and to eliminate weaknesses.
In this study, the vast majority of the false results arose from inadvertent errors by laboratory personnel and not from technical failure of the method as such. The allele-specific PCR assays proved to be less robust than other techniques, however, and the increased error rate of certain LDTs indicates that they, as a group, have to be more carefully validated.
Although the incidence of rare sequence variants interfering with some genotyping techniques is relatively low, the results of samples having such variants can be easily misinterpreted and lead to an even higher error rate. Most of these variants have been discovered because of the unusual melting temperatures observed using hybridization probes with the LightCycler instrument, which is widely used in clinical and research laboratories. Furthermore, all PCR-based methods can be compromised when mutations occur in the primer annealing region, resulting in insufficient amplification, unusual observations, and eventually inconclusive results.
In previous studies, proficiency testing was carried out on the most common SNPs, and those studies did not challenge the competence of testing laboratories to recognize and correctly report sequence variants adjacent to the mutation of interest. The present exercise revealed that where additional sequence variants resulted in unusual genotyping data and were therefore in principle detectable, only a fraction of the laboratories recognized and adequately reported unexpected SNPs.
Although the G20210A mutation is a wellcharacterized risk factor for venous thromboembolism, the consequences of these adjacent variants on the analysis results have been investigated infrequently. Such rare polymorphisms should be reported as variants of unknown clinical significance clearly distinct from the wild-type or G20210A mutation alleles (33 ) . In proficiency testing, most participants reporting the unusual results as technical issues are unlikely to apply another technique to check for the presence of rare sequence variants, as they would usually do for real patient samples.
Interestingly, most of the participants applying sequencing as routine procedure for the detection of the G20210A mutation did not report the C20209T variant, although it could be detected from their raw data. Other laboratories sequenced the fragment to understand the reason for the unusual melting curves and were able to identify the additional mutation. Although the number of participants using sequencing techniques was relatively low in this ring trial, the results correlate with the findings of the recent EQUALseq studies (methodologic European external quality assurance for DNA sequencing) (34 ) , where single-base changes also were often unnoticed. Moreover, participants who claimed to apply screening methods for previously unknown mutations in monogenic disorders did not recognize the rare variants at a higher rate than laboratories predominantly testing for well-defined SNPs.
These observations underline the pivotal importance of the laboratory personnel skills and suggested that training may be an efficient tool to improve the quality of genotyping services (35 ) .
Conclusion
This study revealed that DNA analysis for the detection of the prothrombin G20210A mutation is reliable in a majority of laboratories. However, a fraction of the participants were not able to recognize and adequately report the unusual genotyping results caused by rare SNPs. The majority of failures could be avoided by improved training and careful selection and validation of the methods applied.
